- Aspen bids to acquire 2 GSK thrombosis drugs
Aspen Pharmacare has offered to acquire GlaxoSmithKline's thrombosis drugs Arixtra and Fraxiparine and a related manufacturing site in France. Financial terms of the proposed deal were not disclosed. GSK said the move would be in line with its goal of emphasizing high growth potential. Reuters (6/18)        | Stop banking and start building with GE Capital, Healthcare Financial Services
At GE Capital, we're not just bankers, we're builders. Supporting the growth of life science companies, large and small, as a reliable source of financing is our mission at GE Capital, Healthcare Financial Services. With in-depth industry experience and expertise, our dedicated Life Science Finance team has provided over $1.7 billion in financing over the past 10 years. Stop just banking. And start building. Learn more. | |
- Lilly assumes development of Transition's diabetes drug candidate
Eli Lilly and Co. is exercising a $7 million option to obtain all development and marketing rights to Transition Therapeutics' experimental type 2 diabetes drug TT-401. Transition could get around $240 million more in milestone fees plus royalties if the drug reaches market. "We look forward to continuing the development of TT-401, as it supports our strategy of offering a broad portfolio of therapies for people with diabetes," Lilly official David Moller said. The Wall Street Journal/Dow Jones Newswires (6/17) - Revlimid gets OK in Europe for some patients with MDS
The European Medicines Agency has approved the use of Celgene's Revlimid, or lenalidomide, in some myelodysplastic syndromes patients. The approval covers the use of the drug in patients with low- or intermediate-1-risk myelodysplastic syndrome and deletion 5q chromosomal abnormalities but no other chromosomal abnormalities and who have become dependent on red blood cell transfusions and are not responding to other treatments. MDSBeacon.com (6/17) - Medicago secures patent for making flu virus-like particles in plants
Medicago received a patent in Europe for a process that produces influenza virus-like particles containing hemagglutinin in plants. The protection lasts until mid-2028. "In our opinion, our innovative method of rapidly producing efficacious influenza VLPs is a required technology for strengthened protection of the population against biological threats," said Frederic Ors, Medicago's business development vice president. Pharmaceutical Business Review Online (6/18) - Method allows for generation of nephron progenitor cells
Researchers at Astellas Pharma and Kyoto University have developed a method to produce nephron progenitor cells from human induced pluripotent stem cells and human embryonic stem cells using various chemical compounds and growth factors. Scientists reported at a stem cell research meeting that the differentiated nephron progenitor cells demonstrated the qualities of natural nephron progenitor cells. This points to the potential of the differentiation method in improving regenerative treatments for chronic renal failure and other refractory renal diseases, they say. The Asahi Shimbun (Japan) (6/18)  | Analyst brief: Axendia: Lowering the Cost of Healthcare from the Inside Out
Healthcare administrators are seeking ways to manage a mix of Clinical, Biomedical, Facilities, Engineering and Health IT assets. Learn how Healthcare Executives are leveraging an integrated Enterprise Asset Management solution to enhance patient care and improve clinical outcomes, reduce costs and ensure compliance. |
 | Company & Financial News |  |  | | | Food & Agriculture | | | | | Industrial & Environmental | | | | - BIO thanks lawmaker for renewable chemical amendment to farm bill
BIO praised Rep. Scott Peters, D-Calif., for introducing an amendment to the farm bill that would allow renewable chemical makers to receive support from the Department of Agriculture's Biorefinery Assistance Program. "Eligibility for renewable chemical projects in the Farm Bill Energy Title programs is long overdue. We thank Representative Peters for introducing this language and will work with him to ensure that there is a level playing field in farm bill energy programs," said Brent Erickson, BIO's Industrial and Environmental Section executive vice president. BiofuelsDigest.com (6/18)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Secure document sharing services optimized for life science organizations
ShareVault, a leading provider of highly secure and controlled document sharing solutions and virtual data rooms (VDR), has aligned with BIO to provide companies with significant discounted pricing and complimentary extra features. ShareVault's VDR platform is optimized for life science companies of all sizes and flexibly priced so that even small biotech companies can afford and benefit from its technology. The ShareVault solution is intended for due diligence required during bio-pharma partnering, licensing, fundraising, M&A, clinical study management or other applications that require secure sharing of documents with third parties. Learn more and sign up for a free trial.
| SmartQuote | | | |  | Those who dream by night ... wake in the day to find that it was vanity: but the dreamers of the day are dangerous men, for they may act on their dreams with open eyes, to make it possible."
--T.E. Lawrence,
British army officer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, June 18, 2013
- Monday, June 17, 2013
- Friday, June 14, 2013
- Thursday, June 13, 2013
- Wednesday, June 12, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment